News Sentiment

ALGS sentiment intelligence

Aligos Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.62 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+18.4% over one week, +25.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 18.4% Price confirming higher
Trend fit Trend inactive 25.4% over four weeks
Fair value -52.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 7
Investing.com 7
GlobeNewswire 4
Moomoo 3
simplywall.st 3
Investing News Network 2
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 12
Deals and strategy 10
Analyst action 7
Regulatory and legal 2
Guidance 2
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Investing.com Australia Direct company coverage

H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. following the completion of enrollment in its Phase 2 B-SUPREME trial for chronic hepatitis B virus infection. The trial over-enrolled participants, leading to an anticipated earlie

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 11:58
Source
Investing.com Australia
Investing.com Direct company coverage

H.C. Wainwright reiterates Aligos stock rating on trial enrollment

H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) after the company completed enrollment for its Phase 2 B-SUPREME trial, which is evaluating pevifoscorvir sodium for chronic hepatitis B. Aligos over-enrolled one coho

Tone
Positive 71/100
Event
Analyst action
Published
14 Jul 2026 07:54
Source
Investing.com
Investing News Network Direct company coverage

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Aligos Therapeutics has announced the completion of enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium, a treatment for chronic hepatitis B virus (HBV) infection. The study successfully enrolled both HBeAg+ and HBeAg- participants, with topline safety and efficacy

Tone
Positive 73/100
Event
Market update
Published
14 Jul 2026 01:40
Source
Investing News Network
Moomoo Direct company coverage

Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment

Aligos Therapeutics has announced the completion of enrollment for its Phase 2 study of ALG-000184, an investigational capsid assembly modulator for chronic hepatitis B (CHB). The study aims to evaluate the safety and efficacy of the treatment in patients with CHB, bringing the c

Tone
Positive 71/100
Event
Regulatory and legal
Published
13 Jul 2026 13:42
Source
Moomoo
Investing.com Direct company coverage

Aligos completes enrollment in phase 2 hepatitis B study

Aligos Therapeutics Inc. has completed enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, enrolling 131 HBeAg+ and 114 HBeAg- participants. The company expects topline safety and efficacy data by late Q3 2027. Aligos has also secured a lic

Tone
Positive 75/100
Event
Guidance
Published
13 Jul 2026 12:11
Source
Investing.com
Stock Titan Direct company coverage

Pevifoscorvir HBV trial fully enrolled; first key data expected in late 3Q 2027

Aligos Therapeutics announced the completion of enrollment for its global Phase 2 B-SUPREME study of pevifoscorvir sodium, targeting chronic hepatitis B virus (HBV) infection. Both HBeAg+ and HBeAg- cohorts are now fully enrolled, with 131 and 114 participants respectively. Topli

Tone
Positive 64/100
Event
Market update
Published
13 Jul 2026 11:59
Source
Stock Titan
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (ALGS) Movement

This article provides a real-time analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS) stock movement, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 94.0:1 risk-reward setup, o

Tone
Positive 65/100
Event
Guidance
Published
13 Jul 2026 02:28
Source
Stock Traders Daily
Intellectia AI Direct company coverage

ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison

The article provides an overview of Aligos Therapeutics Inc (ALGS) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors. ALGS maintains a strong gross margin of 100.00% but shows negative operating and net margins, ind

Tone
Negative 29/100
Event
Earnings
Published
10 Jul 2026 01:12
Source
Intellectia AI
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX)

Two healthcare companies, Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX), have received bullish analyst ratings. H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics with a $50 price target, while Truist Financial and Barclays maintained Buy ratings for V

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 11:39
Source
The Globe and Mail
Investing.com Direct company coverage

H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy

H.C. Wainwright has reiterated a Buy rating and $50.00 price target for Aligos Therapeutics (NASDAQ: ALGS), citing the company's differentiated hepatitis B drug candidate, pevifoscorvir sodium. The firm noted that the B-SUPREME trial is nearing full enrollment, and topline primar

Tone
Positive 74/100
Event
Analyst action
Published
09 Jul 2026 11:12
Source
Investing.com
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated its Buy rating and a $50.00 price target for Aligos Therapeutics (NASDAQ:ALGS), citing the potential of its hepatitis B drug candidate, pevifoscorvir sodium, as a differentiated therapy. The company's recent strategic partnership with Xiamen Amoytop

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 11:10
Source
Investing.com Canada
Moomoo Direct company coverage

H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50

H.C. Wainwright has reiterated its Buy rating for Aligos Therapeutics (ALGS.US) and maintained a target price of $50. This continued positive outlook from the analyst firm indicates a strong belief in the company's future performance. Potential investors may view this as a signal

Tone
Positive 75/100
Event
Analyst action
Published
07 Jul 2026 12:39
Source
Moomoo
Investing.com Direct company coverage

Aligos Therapeutics stock jumps on $25M China licensing deal

Aligos Therapeutics Inc. shares surged 21% after announcing a $25 million upfront payment from an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for its chronic hepatitis B drug, pevifoscorvir sodium, in Greater China. The deal also includes up to $420 millio

Tone
Positive 91/100
Event
Deals and strategy
Published
07 Jul 2026 11:39
Source
Investing.com
TradingView Direct company coverage

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

Aligos Therapeutics (ALGS) shares surged 21% after-hours following a $25 million upfront payment from its Chinese licensing partner, Xiamen Amoytop Biotech. This payment provides non-dilutive funding, bolstering Aligos's financial position, which stood at $54.9 million in cash as

Tone
Positive 92/100
Event
Deals and strategy
Published
06 Jul 2026 23:40
Source
TradingView
Moomoo Direct company coverage

Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech

Aligos Therapeutics (ALGS) shares rallied after receiving a $25 million milestone payment from its partner Xiamen Amoytop Biotech. This payment was triggered by the investigational new drug (IND) approval for a new compound targeting chronic hepatitis B (CHB). The collaboration,

Tone
Positive 94/100
Event
Regulatory and legal
Published
06 Jul 2026 22:40
Source
Moomoo
Investing.com South Africa Direct company coverage

Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com

Aligos Therapeutics (NASDAQ: ALGS) saw its stock jump 21% in after-hours trading following a licensing deal with Xiamen Amoytop Biotech Co., Ltd., which includes a $25 million upfront payment. The agreement grants Amoytop exclusive rights to develop and commercialize pevifoscorvi

Tone
Positive 72/100
Event
Deals and strategy
Published
06 Jul 2026 22:10
Source
Investing.com South Africa
Investing News Network Direct company coverage

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics (Nasdaq: ALGS) has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. This deal also includes potential milestone paymen

Tone
Positive 72/100
Event
Deals and strategy
Published
06 Jul 2026 20:40
Source
Investing News Network
Investing.com Direct company coverage

Aligos receives $25M upfront payment from China licensing deal

Aligos Therapeutics Inc. has received a $25 million upfront payment from its licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for pevifoscorvir sodium in Greater China. The deal includes potential milestone payments of up to $420 million and royalties, extending Aligos's

Tone
Positive 74/100
Event
Deals and strategy
Published
06 Jul 2026 20:39
Source
Investing.com
Stock Titan Direct company coverage

China grants breakthrough status to Aligos’ HBV drug after $25M deal

Aligos Therapeutics has received a $25 million upfront payment from Amoytop for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B. The drug has also been granted Breakthrough Therapy Designation in China, making it eligible for priority review

Tone
Positive 74/100
Event
Deals and strategy
Published
06 Jul 2026 19:39
Source
Stock Titan
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in ALGS Response

This article provides an in-depth analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS), highlighting mixed sentiment and choppy conditions across various time horizons. It details specific institutional trading strategies, including position, momentum, and risk hedging, with defin

Tone
Negative 38/100
Event
Market update
Published
02 Jul 2026 01:40
Source
Stock Traders Daily
Stock Titan Direct company coverage

Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50

Aligos Therapeutics director Heather Preston was granted 5,860 stock options with an exercise price of $5.50 per share, expiring on June 25, 2036. These options will vest fully on the earlier of the first anniversary of the June 25, 2026 grant date or just before the company’s 20

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 08:10
Source
Stock Titan
Stock Titan Direct company coverage

Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike

Aligos Therapeutics director Margarita Chavez was granted 5,860 stock options with an exercise price of $5.50 per share, expiring in 2036. These options will vest 100% on the earlier of the first anniversary of the June 25, 2026 grant date or Aligos Therapeutics' 2027 annual stoc

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:41
Source
Stock Titan
Stock Titan Direct company coverage

Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50

Aligos Therapeutics director Peter Hirth was granted stock options for 5,860 shares at an exercise price of $5.50 per share. These options will vest on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, provided conti

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:41
Source
Stock Titan
Stock Titan Direct company coverage

Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike

Aligos Therapeutics director Bridget A. Martell was granted 5,860 stock options at an exercise price of $5.50 per share. These options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company's 2027 annual stockholder meeting, continge

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:41
Source
Stock Titan